DUSA PHARMACEUTICALS, INC.

DUSA PHARMACEUTICALS, INC.

January 04, 2005 08:01 ET

DUSA Announces Hiring of Robert Doman as President and Chief Operating Officer


NEWS RELEASE TRANSMITTED BY CCNMatthews

FOR: DUSA PHARMACEUTICALS, INC.

NASDAQ SYMBOL: DUSA

JANUARY 4, 2005 - 08:01 ET

DUSA Announces Hiring of Robert Doman as President and
Chief Operating Officer

WILMINGTON, MASSACHUSETTS--(CCNMatthews - Jan. 4, 2005) - DUSA
Pharmaceuticals, Inc. (NASDAQ NMS:DUSA) today announced the hiring of
Robert Doman as President and Chief Operating Officer (COO) of the
Company, based at DUSA's Wilmington, MA headquarters, effective January
3rd, 2005. Mr. Doman has more than 25 years experience in the medical
device industry, with domestic and international experience in general
management, acquisitions/licensing, business development, sales,
marketing and strategic planning.

From 2000 until 2004, Mr. Doman served as President of Leach Technology
Group, the medical device division of Leach Holding Corporation, a
privately owned company that was recently sold to Esterline Technologies
(NYSE:ESL).

From 1999 to 2000, he was President, Device Product Development, of West
Pharmaceutical Services (NYSE:WST), a manufacturer of systems and device
components for parenterally administered medicines and drugs.

Prior to joining West Pharmaceutical Services, he worked for the
Convatec division of Bristol-Myers Squibb from 1991 to 1999 in positions
that included: Vice President, Worldwide Marketing and Business
Development; Vice President and General Manager, U.S. Wound and Skin
Care; and Vice President, U.S. Operations. During this time, he also had
significant exposure to the field of dermatology.

From 1976 until 1990, he worked for Critikon, Inc., a Johnson & Johnson
company, in various sales, sales management and marketing positions,
eventually rising to become Business Director of the Vascular Access
Unit.

Dr. Geoffrey Shulman, DUSA's former President and Chief Executive
Officer (CEO), is remaining as CEO, and has been re-appointed as the
Chairman of the Board of Directors. Jay Haft, DUSA's former Chairman, is
remaining the Company's Lead Director and has been appointed to the new
position of Vice Chairman of the Board of Directors.

Dr. Shulman, DUSA's CEO, stated "With DUSA's rapid sales growth in 2004,
and our expectations of continued strong growth in the years to come, we
felt that it was important to add additional experienced professional
management to help lead DUSA's growth during this critical period.
Therefore, we are delighted to have Bob Doman join DUSA as President and
COO. Bob is a proven winner who has been a successful leader and
professional manager with both small and large companies throughout his
career. The management team and I look forward to working with him to
take DUSA to a whole new level of success in the years to come."

Commenting on the appointment, Mr. Doman stated, "I am thrilled to be
joining DUSA at such an exciting time in the Company's history. DUSA has
significant potential for growth based on its core technology in
Levulan® Photodynamic Therapy (PDT) and Photodetection (PD),
compelling clinical data and dedicated employees. I am very excited
about the opportunity to work with the management team and employees to
bring this technology to medical professionals for the benefit of their
patients."

DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged
primarily in the development of Levulan PDT and PD for multiple medical
conditions, with its primary focus in dermatology. PDT and PD utilize
light-activated compounds to induce a therapeutic or detection effect.
DUSA is a world leader in topically or locally applied PDT and PD. DUSA
maintains offices in Wilmington, MA, Valhalla, NY and Toronto, Ontario.

Except for historical information, this news release contains certain
forward-looking statements that involve known and unknown risks and
uncertainties, which may cause actual results to differ materially from
any future results, performance or achievements expressed or implied by
the statements made. These forward-looking statements relate to the
Company's expectations and significant potential for continued strong
growth and working with Mr. Doman in the future to reach new levels of
success. Such risks and uncertainties include, but are not limited to,
DUSA's continued sales penetration, continuing regulatory approval of
its products, market acceptance of future products, DUSA's ability to
continue to fund its anticipated growth plans, maintenance of its patent
portfolio and other risks identified in our SEC filings from time to
time, including those contained in DUSA's Form 10-K for the year ended
December 31, 2003.

-30-

Contact Information

  • FOR FURTHER INFORMATION PLEASE CONTACT:
    DUSA Pharmaceuticals, Inc.
    D. Geoffrey Shulman, MD
    President and CEO
    (416) 363-5059
    or
    DUSA Pharmaceuticals, Inc.
    Shari Lovell
    Director, Shareholder Services
    (416) 363-5059
    (416) 363-6602 (FAX)
    or visit www.dusapharma.com